KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials
By:
Business Wire
April 17, 2025 at 21:08 PM EDT
Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.
The release was issued in error by Aditxt, Inc.
A replacement release will not be issued at this time.
Contacts
Aditxt, Inc.
Corporate Communications
Jeff Ramson, PCG Advisory, Inc.
T: 646-863-6893
contactus@aditxt.com
More News
View MoreVia MarketBeat
Why Palantir Slide May Be a Setup for a Long-Term Opportunity ↗
Today 10:36 EST
Via MarketBeat
Attention Income Investors: This REIT Is on Sale ↗
Today 9:01 EST
Via MarketBeat
Tickers
RKLB
MarketBeat Week in Review – 11/17 - 11/21 ↗
Today 7:00 EST
Recent Quotes
View More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>